Xeris Pharmaceuticals Inc(XERS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

XERS Xeris Pharmaceuticals Inc

Trading 07-16 15:05:37 EDT

8.68

-0.02

-0.23%

High8.88	Low8.67	Vol889.20K
Open8.70	D1 Closing8.70	Amplitude2.36%
Mkt Cap1.50B	Tradable Cap1.41B	Total Shares172.43M
T/O7.78M	T/O Rate0.55%	Tradable Shares162.54M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"XERS","market":"US","secType":"STK","nameCN":"Xeris Pharmaceuticals Inc","latestPrice":8.68,"timestamp":1784228736687,"preClose":8.7,"halted":0,"volume":889197,"delay":0,"changeRate":-0.002298850574712595,"floatShares":162543400,"shares":172431290,"eps":0.069554314,"marketStatus":"Trading","change":-0.02,"latestTime":"07-16 15:05:37 EDT","open":8.7,"high":8.875,"low":8.67,"amount":7784452.017378001,"amplitude":0.023563,"askPrice":8.69,"askSize":300,"bidPrice":8.68,"bidSize":729,"shortable":3,"etf":0,"ttmEps":0.069554314,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1784232000000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1529553600000,"exchange":"NASDAQ","adjPreClose":8.7,"preHourTrading":{"tag":"盘前","latestPrice":8.71,"preClose":8.7,"latestTime":"09:29 EDT","volume":19275,"amount":165174.5200125,"timestamp":1784208567005,"change":0.01,"changeRate":0.001149,"amplitude":0.037931},"postHourTrading":{"tag":"盘后","latestPrice":8.7,"preClose":8.7,"latestTime":"19:15 EDT","volume":82172,"amount":713896.81,"timestamp":1784157327581,"change":0,"changeRate":0,"amplitude":0.034483},"volumeRatio":0.668749,"impliedVol":0.9106,"impliedVolPercentile":0.5896},"requestUrl":"/m/hq/s/XERS","defaultTab":"news","newsList":[{"id":"2649958307","title":"Xeris Biopharma CFO Steven Pieper Disposes of 45,000 Common Shares Worth $385,876.20","url":"https://stock-news.laohu8.com/highlight/detail?id=2649958307","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649958307?lang=en_us&edition=fundamental","pubTime":"2026-07-08 05:11","pubTimestamp":1783458719,"startTime":"0","endTime":"0","summary":"Xeris Biopharma CFO Steven Pieper disposes of 45,000 common shares worth $385,876.20Xeris Biopharma CFO Steven Pieper sold 45,000 common shares in two trades on July 6-7, SEC filing shows.Sales priced","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nNDL3SgY8N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Xeris Biopharma CFO Steven Pieper Disposes of 45,000 Common Shares Worth $385,876.20","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","XERS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649649033","title":"Xeris Names John Shannon as Chair of the Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2649649033","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649649033?lang=en_us&edition=fundamental","pubTime":"2026-07-06 15:21","pubTimestamp":1783322486,"startTime":"0","endTime":"0","summary":"June 30 (Reuters) - Xeris Biopharma Holdings Inc::*XERIS ANNOUNCES UPDATES TO ITS BOARD OF DIRECTORS*XERIS BIOPHARMA HOLDINGS - APPOINTS JOHN SHANNON AS CHAIR OF THE BOARD*XERIS BIOPHARMA HOLDINGS - M","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nRSD848rYw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","XERS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649974226","title":"Why Xeris Biopharma (XERS) Is Up 7.7% After Governance, IP, And Balance Sheet Moves - And What's Next","url":"https://stock-news.laohu8.com/highlight/detail?id=2649974226","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649974226?lang=en_us&edition=fundamental","pubTime":"2026-07-05 08:26","pubTimestamp":1783211218,"startTime":"0","endTime":"0","summary":"Xeris Biopharma Holdings recently combined governance and capital structure moves, including appointing CEO John Shannon as Board Chair, adding experienced biotech executive and physician Dr. Nerissa Kreher to expand the Board to eight directors, securing a USPTO notice of allowance for a Keveyis patent expected to extend protection through 2039, and retiring about US$23,000,000 of its 8.00% Convertible Senior Notes due 2028.\nTaken together, these leadership changes, intellectual property...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xers/xeris-biopharma-holdings/news/why-xeris-biopharma-xers-is-up-77-after-governance-ip-and-ba","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xers/xeris-biopharma-holdings/news/why-xeris-biopharma-xers-is-up-77-after-governance-ip-and-ba","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","AIPO","BK4588","IP","LU1169589451.USD","LU1481599808.USD","CUT","XERS","LU1169590202.USD","LU1481600234.SGD","LU1487256676.USD","IE00B3T34201.USD","WOOD","BK4136","LU2463526074.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648636191","title":"Xeris Biopharma Director Nerissa Kreher Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2648636191","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648636191?lang=en_us&edition=fundamental","pubTime":"2026-07-03 06:00","pubTimestamp":1783029615,"startTime":"0","endTime":"0","summary":"Xeris Biopharma director Nerissa Kreher files initial beneficial ownership statementXeris Biopharma filed an initial Form 3 for director Nerissa Kreher, dated July 1.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xeris Biopharma Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on July 02, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260702:nNDLg02Rk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","XERS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648633176","title":"Xeris Biopharma Chief Legal Officer Beth Hecht Sells 16,666 Shares Worth $133,865.06","url":"https://stock-news.laohu8.com/highlight/detail?id=2648633176","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648633176?lang=en_us&edition=fundamental","pubTime":"2026-07-03 04:40","pubTimestamp":1783024819,"startTime":"0","endTime":"0","summary":"Xeris Biopharma Chief Legal Officer Beth Hecht sells 16,666 shares worth $133,865.06Xeris Biopharma Chief Legal Officer, Corporate Secretary Beth Hecht sold 16,666 common shares on July 1.Shares were ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260702:nNDL9jxm4x:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Xeris Biopharma Chief Legal Officer Beth Hecht Sells 16,666 Shares Worth $133,865.06","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XERS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648384966","title":"Xeris Biopharma Grants 221,323 Inducement Rsus to 47 New Employees","url":"https://stock-news.laohu8.com/highlight/detail?id=2648384966","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648384966?lang=en_us&edition=fundamental","pubTime":"2026-07-03 04:05","pubTimestamp":1783022742,"startTime":"0","endTime":"0","summary":"Xeris Biopharma grants 221,323 inducement RSUs to 47 new employeesXeris Biopharma granted restricted stock units covering 221,323 common shares to 47 new employees on July 1, 2026.Awards were issued u","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260702:nNDL1WP1cr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XERS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647555385","title":"Xeris Taps CEO to Additionally Serve as Chairman","url":"https://stock-news.laohu8.com/highlight/detail?id=2647555385","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647555385?lang=en_us&edition=fundamental","pubTime":"2026-06-30 20:10","pubTimestamp":1782821400,"startTime":"0","endTime":"0","summary":"Xeris Biopharma said its board appointed John Shannon as chairman, effective July 1, nearly two years after he assumed the role of chief executive.Shannon succeeds Marla Persky as chair of the board, though Persky will remain on the board as lead independent director, the biopharmaceutical company said Tuesday.\"When John was appointed CEO, the board wanted him to focus on strategy and growth,\" Persky said. She added that in the time since, he has clearly demonstrated the leadership and vision necessary to advance the company.\"His successes, combined with his deep understanding of the business, clearly demonstrate that John is the ideal person to now also serve as chairman,\" she said.Shannon joined Xeris in 2017 as chief operating officer. He was previously promoted to president in 2020.Xeris also on Tuesday appointed Nerissa Kreher to its board, expanding it to eight members.Kreher currently serves as chief medical officer of Alltrna, where she leads clinical development, regulatory an","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XERS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647558911","title":"Palvella Therapeutics Appoints Savara CEO Matt Pauls to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2647558911","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647558911?lang=en_us&edition=fundamental","pubTime":"2026-06-30 19:31","pubTimestamp":1782819065,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics appoints Savara CEO Matt Pauls to board of directorsPalvella Therapeutics appointed Matt Pauls to its board as it prepares for a potential US launch of QTORIN rapamycin.Pauls is ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nNDL9zc8Wg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","IE00BN0W2W23.USD","IE00B3QW5Z07.USD","BK4007","SG9999014013.SGD","LU2210149790.SGD","IE00BN0W2T93.GBP","LU0314104364.USD","BK4139","PVLA","IE00BGHQF748.EUR","BK4585","LU2095319765.USD","SG9999014021.USD","SG9999014005.SGD","IE00B64PRP62.GBP","SVRA","IE00BN0W2V16.EUR","IE00BKPKM429.USD","XERS","BK4588","BK4112","NDAQ","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647309835","title":"Xeris Names CEO John Shannon Board Chair, Effective July 1, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2647309835","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647309835?lang=en_us&edition=fundamental","pubTime":"2026-06-30 19:00","pubTimestamp":1782817219,"startTime":"0","endTime":"0","summary":"Xeris names CEO John Shannon board chair, effective July 1, 2026Xeris Biopharma named CEO John Shannon chair of the board, effective July 1, 2026.Marla Persky stepped down as chair, remaining on the b","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nNDL4d2jDk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TECX","XERS","BK4139","BK4007","TRDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647653065","title":"Xeris Announces Updates to Its Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2647653065","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647653065?lang=en_us&edition=fundamental","pubTime":"2026-06-30 19:00","pubTimestamp":1782817201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nTUA520K6Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["XERS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647530997","title":"Xeris Biopharma Holdings - Marla Persky to Transition to Lead Independent Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2647530997","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647530997?lang=en_us&edition=fundamental","pubTime":"2026-06-30 19:00","pubTimestamp":1782817201,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nTUA520K6Z:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["XERS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647309905","title":"Xeris Biopharma Holdings - Appoints John Shannon as Chair of the Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2647309905","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647309905?lang=en_us&edition=fundamental","pubTime":"2026-06-30 19:00","pubTimestamp":1782817201,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nTUA520K6Z:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["XERS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642234787","title":"Xeris Biopharma Gets Notice of Allowance From US Patent and Trademark Office for New KEVEYIS Patent","url":"https://stock-news.laohu8.com/highlight/detail?id=2642234787","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642234787?lang=en_us&edition=fundamental","pubTime":"2026-06-12 04:51","pubTimestamp":1781211089,"startTime":"0","endTime":"0","summary":"Xeris Biopharma  said late Thursday the United States Patent and Trademark Office has issued a notice of allowance to US patent application No. 17/151,405, entitled \"Compositions and Methods of Use\" for its KEVEYIS product.Following this issuance, the company will submit the patent to the US Food and Drug Administration for listing in the FDA's publication \"Approved Drug Products with Therapeutic Equivalence Evaluations\", commonly known as the Orange Book, the company said.The new patent will provide intellectual property protection for KEVEYIS through 2039, the company added.KEVEYIS is an FDA-approved treatment for primary periodic paralysis.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XERS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642723494","title":"Xeris Biopharma gets USPTO notice of allowance for Keveyis patent extending protection to 2039","url":"https://stock-news.laohu8.com/highlight/detail?id=2642723494","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642723494?lang=en_us&edition=fundamental","pubTime":"2026-06-12 04:39","pubTimestamp":1781210356,"startTime":"0","endTime":"0","summary":"Xeris Biopharma received a USPTO Notice of Allowance for a new U.S. patent application covering use of its Keveyis  product.The patent is expected to provide intellectual property protection for Keveyis through 2039, subject to issuance and maintenance fees.Xeris plans to submit the patent to the FDA for listing in the Orange Book once it issues.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nNDL4WpHTY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XERS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642223320","title":"Analysts Are Bullish on Top Healthcare Stocks: Omnicell (OMCL), Xeris Pharmaceuticals (XERS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2642223320","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642223320?lang=en_us&edition=fundamental","pubTime":"2026-06-11 23:40","pubTimestamp":1781192444,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Omnicell (OMCL) and Xeris Pharmaceuticals (XERS) wit...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-omnicell-omcl-xeris-pharmaceuticals-xers-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-omnicell-omcl-xeris-pharmaceuticals-xers-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4082","BK4112","BLSG","XLV","HCSG","LU0128526141.USD","BLSH","LU0029874061.USD","OMCL","BLSX","BK4167","BK4588","BK4585","BK4137","XBI","XERS","LABU","BK4581","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642289636","title":"Xeris Biopharma announces private exchange of convertible notes","url":"https://stock-news.laohu8.com/highlight/detail?id=2642289636","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642289636?lang=en_us&edition=fundamental","pubTime":"2026-06-11 19:11","pubTimestamp":1781176301,"startTime":"0","endTime":"0","summary":"Xeris Biopharma (XERS) entered into separate, privately negotiated exchange agreements with certain holders of its 8.00% Convertible Senior Notes d...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/xeris-biopharma-announces-private-exchange-of-convertible-notes-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/xeris-biopharma-announces-private-exchange-of-convertible-notes-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","XERS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642286773","title":"BRIEF-Xeris Biopharma Announces Private Exchange Of Convertible Notes","url":"https://stock-news.laohu8.com/highlight/detail?id=2642286773","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642286773?lang=en_us&edition=fundamental","pubTime":"2026-06-11 19:05","pubTimestamp":1781175921,"startTime":"0","endTime":"0","summary":"BRIEF-Xeris Biopharma Announces Private Exchange Of Convertible NotesJune 11 (Reuters) - Xeris Biopharma Holdings Inc XERS.O:XERIS BIOPHARMA ANNOUNCES PRIVATE EXCHANGE OF CONVERTIBLE NOTESXERIS BIOPHA","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nTUA6SMJN9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XERS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642286108","title":"Xeris Biopharma retires USD 23 million of 8% convertible notes in cash-and-stock exchange","url":"https://stock-news.laohu8.com/highlight/detail?id=2642286108","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642286108?lang=en_us&edition=fundamental","pubTime":"2026-06-11 19:00","pubTimestamp":1781175635,"startTime":"0","endTime":"0","summary":"Xeris Biopharma struck private exchanges to retire USD 23 million of 8.00% Convertible Senior Notes due 2028.Consideration: about USD 23 million cash; remaining value paid in common stock based on a 21-day VWAP starting June 11, 2026.At a USD 6.71 reference price, stock issuance would total about 4,600,000 shares.Transaction cuts debt by about USD 23 million; annual interest savings estimated at about USD 2 million.Notes outstanding expected to fall to USD 10.5 million once the exchanges close.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nNDL5LQdpx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XERS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642286137","title":"Xeris Biopharma Announces Private Exchange of Convertible Notes","url":"https://stock-news.laohu8.com/highlight/detail?id=2642286137","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642286137?lang=en_us&edition=fundamental","pubTime":"2026-06-11 19:00","pubTimestamp":1781175601,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nTUA6SMJN9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","XERS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642261286","title":"Xeris Biopharma - to Retire $23 Mln Principal of Notes for $23 Mln Cash and Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2642261286","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642261286?lang=en_us&edition=fundamental","pubTime":"2026-06-11 19:00","pubTimestamp":1781175601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nTUA6SMJN9:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["XERS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.xerispharma.com","stockEarnings":[{"period":"1week","weight":0.0035},{"period":"1month","weight":0.2645},{"period":"3month","weight":0.4216},{"period":"6month","weight":0.1569},{"period":"1year","weight":0.6446},{"period":"ytd","weight":0.1083}],"compareEarnings":[{"period":"1week","weight":0.0126},{"period":"1month","weight":0},{"period":"3month","weight":0.0757},{"period":"6month","weight":0.0913},{"period":"1year","weight":0.2132},{"period":"ytd","weight":0.1069}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.","yearOnYearQuotes":[{"month":1,"riseRate":0.375,"avgChangeRate":-0.070057},{"month":2,"riseRate":0.625,"avgChangeRate":-0.03111},{"month":3,"riseRate":0.5,"avgChangeRate":-0.033138},{"month":4,"riseRate":0.5,"avgChangeRate":0.033714},{"month":5,"riseRate":0.75,"avgChangeRate":0.150943},{"month":6,"riseRate":0.5,"avgChangeRate":-0.023256},{"month":7,"riseRate":0.555556,"avgChangeRate":0.002225},{"month":8,"riseRate":0.625,"avgChangeRate":0.207997},{"month":9,"riseRate":0.375,"avgChangeRate":-0.064053},{"month":10,"riseRate":0.5,"avgChangeRate":-0.004147},{"month":11,"riseRate":0.5,"avgChangeRate":-0.025098},{"month":12,"riseRate":0.625,"avgChangeRate":0.051713}],"exchange":"NASDAQ","name":"Xeris Pharmaceuticals Inc","nameEN":"Xeris Pharmaceuticals Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Xeris Pharmaceuticals Inc(XERS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Xeris Pharmaceuticals Inc(XERS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Xeris Pharmaceuticals Inc,XERS,Xeris Pharmaceuticals Inc股票,Xeris Pharmaceuticals Inc股票老虎,Xeris Pharmaceuticals Inc股票老虎国际,Xeris Pharmaceuticals Inc行情,Xeris Pharmaceuticals Inc股票行情,Xeris Pharmaceuticals Inc股价,Xeris Pharmaceuticals Inc股市,Xeris Pharmaceuticals Inc股票价格,Xeris Pharmaceuticals Inc股票交易,Xeris Pharmaceuticals Inc股票购买,Xeris Pharmaceuticals Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Xeris Pharmaceuticals Inc(XERS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Xeris Pharmaceuticals Inc(XERS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction